Nuvation Bio Inc— Fundamentals deep dive
Five-year ratio trends, valuation spread across DCF / EPV / EV-revenue, quality scores, statement history, and peer positioning forNUVB. A companion to the NUVBsnapshot.
Composite Fair Value
$1.21
Upside / Downside
-76.0%
Signal
Overvalued
Implied Growth
--
EV/Rev
$1.21
Altman Z
0.45
Distress
Piotroski
4
Moderate (4-6)
Cash Conversion
0.85x
Rule of 40
410.0%
Elite
After signup
Run your own DCF in the app
Adjust growth, discount, and terminal assumptions instead of accepting this composite snapshot.
Compare the six valuation models side-by-side and save your thesis, not just read a static page.
Carry the valuation into watchlist, alerts, and scenario backtests.
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-120M | $-104M | $-96M |
| 2023-12-31 | $0 | $-100M | $-76M | $-68M |
| 2024-12-31 | $8M | $-168M | $-568M | $-131M |
| 2025-12-31 | $63M | $-213M | $-205M | $-182M |
After signup
Open the full statement deep-dive
Extend history beyond this four-year public window into longer cycles.
Drill from summary lines into working capital, debt, capex, and cash-flow detail.
Cross-link statement changes with alerts and saved workflows.
Ready to run your own scenarios onNUVB?
Tune DCF assumptions, compare against custom peer sets, layer in conviction and regime context, and save the thesis to your watchlist.
For informational and educational purposes only. Not financial advice. Learn more